Technical Snapshots for These Drug Makers Stocks -- AstraZeneca, Impax Laboratories, TherapeuticsMD, and GlaxoSmithKline

Monday, November 13, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 13, 2017 /PRNewswire/ --

If you want a Stock Review on AZN, IPXL, TXMD, or GSK then come over to

and sign up for your free customized report. Drug Manufacturers companies develop and sell medicines and vaccines for a wide range of medical uses. Most of them are structured as corporations, and many offer slightly higher-than-average dividend yields.
Ahead of today's trading session, observes the performance of four major players in this space: AstraZeneca PLC (NYSE: AZN), Impax Laboratories Inc. (NASDAQ: IPXL), TherapeuticsMD Inc. (NASDAQ: TXMD), and GlaxoSmithKline PLC (NYSE: GSK). Access's complimentary reports for today's stocks line-up at:


Cambridge, the UK headquartered AstraZeneca PLC's stock finished last Friday's session 0.60% lower at $32.91. A total volume of 4.92 million shares was traded, which was above their three months average volume of 4.16 million shares. The Company's shares have advanced 13.09% over the previous three months and 20.46% since the start of this year. The stock is trading above its 200-day moving average by 3.33%. Additionally, shares of AstraZeneca, which discovers, develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have a Relative Strength Index (RSI) of 36.90.  

On October 16th, 2017, research firm Credit Suisse upgraded the Company's stock rating from 'Neutral' to 'Outperform'.

On November 08th, 2017, AstraZeneca announced that it and its global biologics R&D arm, MedImmune, will be underlining their scientific focus on cardiovascular, renal, and metabolic diseases with 28 presentations, including two late-breaking trials, at the American Heart Association Scientific Sessions taking place from November 11th, 2017, to November 15th, 2017 in Anaheim, California. Visit us today and access your complete report on AZN for free at:

Impax Laboratories

On Friday, shares in Hayward, California headquartered Impax Laboratories Inc. ended the session 6.71% higher at $18.30. The stock recorded a trading volume of 1.39 million shares. The Company's shares have gained 2.81% in the previous three months and 38.11% on an YTD basis. The stock is trading 12.96% above its 200-day moving average. Moreover, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 43.89.  

On November 08th, 2017, Impax Labs announced that it is mourning the loss of Richard A. Bierly, a member of its Board of Directors, who recently passed away. Appointed in August 2016, Mr. Bierly also served on the Board's Audit and Compensation Committees. He had a long and successful finance career in the Pharmaceutical industry, most recently serving as CFO of Medivation, Inc., a biopharmaceutical company acquired by Pfizer in 2016. The complimentary research report on IPXL can be accessed at:


Boca Raton, Florida headquartered TherapeuticsMD Inc.'s shares gained 1.07%, closing the session at $5.67 with a total trading volume of 2.03 million shares. The stock has surged 21.15% in the last one month. The Company's shares are trading 3.70% and 2.38% above their 50-day and 200-day moving averages, respectively. Additionally, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 57.95.  

On November 07th, 2017, TherapeuticsMD announced that it will participate in the Stifel 2017 Healthcare Conference on November 14th, 2017, at 8:00 a.m. ET. The Company will also participate in the Jefferies 2017 London Healthcare Conference on November 16th, 2017, 3:40 a.m. ET. CEO Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D. will participate in both conferences. Register for free on and download the research report on TXMD at:


Last Friday at the close, shares in Brentford, the UK headquartered GlaxoSmithKline PLC recorded a trading volume of 5.96 million shares, which was above their three months average volume of 4.25 million shares. The stock ended the session 1.31% lower at $35.30. The Company's shares are trading below their 50-day moving average by 10.67%. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 23.94.  

On November 01st, 2017, GlaxoSmithKline and Innoviva, Inc. announced positive data from a study comparing a once-daily, long-acting, muscarinic antagonist and a long-acting, beta agonist, fixed-dose combination, Anoro Ellipta (umeclidinium/vilanterol 62.5mcg/25mcg; UMEC/VI) and Stiolto Respimat (tiotropium/olodaterol 5mcg/5mcg; TIO/OLO), for symptomatic patients with chronic obstructive pulmonary disease. The data were published that day in Advances in Therapy and were also presented at the CHEST annual meeting of the American College of Chest Physicians in Toronto, Canada.

On November 06th, 2017, research firm Investec downgraded the Company's stock rating from 'Buy' to 'Hold'. Get free access to your research report on GSK at:


Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


View original content:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store